Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 382-388

  Dicko, Alassane ^a   Santara, Gaoussou ^a   Mahamar, Almahamoudou ^a   Sidibe, Youssoufa ^a   Barry, Amadou ^a   Dicko, Yahia ^a   Diallo, Aminata ^b   Dolo, Amagana ^a   Doumbo, Ogobara ^a   Shafi, Fakrudeen ^c   Francois, Nancy ^d   Strezova, Ana ^d   Borys, Dorota ^d   Schuerman, Lode ^d  

^a UNIVERSITY OF BAMAKO   (Mali)

^b Service de Pediatrie   (Mali)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d GSK   (Belgium)

Author keywords

Antibody persistence; Booster; Immunogenicity; Mali; PHiD CV; Pneumococcal conjugate vaccine; Reactogenicity; Safety

Indexed keywords

BACTERIAL VACCINE; PNEUMOCOCCAL NONTYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; BACTERIUM ANTIBODY; OPSONIN; PHID-CV VACCINE;

ANOREXIA; ANTIBODY TITER; ARTICLE; BRONCHITIS; CHILD; DROWSINESS; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALE; MALI; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; RHINITIS; SIDE EFFECT; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HAEMOPHILUS INFECTIONS; IMMUNIZATION; IMMUNOLOGY; INCIDENCE; INFANT; PATHOLOGY;

ANTIBODIES, BACTERIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HAEMOPHILUS INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; MALE; MALI; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES;

EID: 84874671315     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22692     Document Type: Article

References (30)

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al.; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969-87; PMID:20466419; http://dx.doi.org/10.1016/S0140-6736(10)60549- 1.
2. Global Alliance for Vaccines and Immunization (GAVI): Advance Market Commitments for Vaccines Update: World's Poorest Children Among First to Receive New Life-Saving Pneumococcal Vaccines.2010 [http://www.vaccineamc.org/ updatemar23-10 html]
3. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005 5:83-93; PMID:15680778. (Pubitemid 40174779)
4. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Hance LF, Reithinger R, et al. Systemic evaluation of serotypes causing invasive pneumococcal disease among children under five: the global serotype project. PLoS Med 2010 7:10; http://dx.doi.org/10.1371/journal. pmed.1000348.
5. World Health Organization (WHO). Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007 82:93-104; PMID:17380597.
6. Saaka M, Okoko BJ, Kohberger RC, Jaffar S, Enwere G, Biney EE, et al. Immunogenicity and serotypespecific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. Vaccine 2008; 26:3719-26; PMID:18514974; http://dx.doi.org/10.1016/j.vaccine. 2008.04.066.
7. Klugman KP, Madhi SA, Adegbola RA, Cutts F, Greenwood B, Hausdorff WP. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine 2011; 29:3372-3; PMID:21396901; http://dx.doi.org/10.1016/ j.vaccine.2011.02.089.
8. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010; 16:402-10; PMID:20132251; http://dx.doi.org/10.1111/j.1469-0691.2010.03182.x.
9. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of sevenvalent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495-502; PMID:17071283; http://dx.doi.org/10.1016/S0140-6736(06)69637-2. (Pubitemid 44634693)
10. Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health 2011; 11:882-93; PMID:22112189; http://dx.doi.org/10.1186/1471-2458-11-882.
11. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 2009; 28(Suppl):S109-18; PMID:19325447; http://dx.doi.org/10.1097/INF.0b013e318199f62d.
12. Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009; 28(Suppl):S77-88; PMID:19325450; http://dx.doi.org/10.1097/INF. 0b013e318199f609.
13. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiDCV). Pediatr Infect Dis J 2009; 28(Suppl):S97-108; PMID:19325452; http://dx.doi.org/10.1097/INF.0b013e318199f61b.
14. Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009; 28:e276-82; PMID:20118683; http://dx.doi.org/10.1097/INF.0b013e3181b48ca3.
15. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339-50; PMID:19837254; http://dx.doi.org/10.1016/S0140-6736(09)61208-3.
16. Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measlesmumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J 2010; 29:e47-56; PMID:20508478; http://dx.doi.org/10.1097/ INF.0b013e3181dffabf.
17. Bermal N, Szenborn L, Edison A, Hernandez M, Pejcz J, Majda-Stanislawska E, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J 2011; 30:69-72; PMID:20980933; http://dx.doi.org/10.1097/INF.0b013e3181f2da06.
18. Lagos RE, Munoz AE, Levine MM, Lepetic A, Francois N, Yarzabal JP, et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin 2011; 7:511-22; PMID:21441782; http://dx.doi.org/10.4161/hv.7.5.14634.
19. Kim CH, Kim JS, Cha SH, Kim KN, Kim JD, Lee KY, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J 2011; 30:e235-43; PMID:21817957; http://dx.doi.org/10.1097/INF. 0b013e31822a8541.
20. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9. (Pubitemid 43326292)
21. Hausdorff WP, Hoet B, Schuerman L Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010 10 4 PMID:20122261 http://dx.doi.org/10.1186/1471-2431-10-4.
22. De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiDCV in the province of Quebec, Canada. Vaccine 2012; 30:6416-20; PMID:22921290; http://dx.doi.org/10.1016/j.vaccine.2012.08.017.
23. Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, et al. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanuspertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 1998; 16:921-7; PMID:9682338; http://dx.doi.org/10.1016/S0264-410X(97) 00303-4. (Pubitemid 28276002)
24. Lagos R, Hoffenbach A, Scemama M, Dupuy M, Schodel F, Hessel L, et al. Lot-to-lot consistency of a combined hexavalent diptheria-tetanus- acellularpertussis, hepatitis B, Inactivated polio and haemophilus B conjugate vaccine, administered to healthy chilean infants at two, four and six months of age. Hum Vaccin 2005; 1:112-7; PMID:17012870; http://dx.doi.org/10.4161/hv.1.3. 1848.
25. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009; 28(Suppl):S89-96; PMID:19325451; http://dx.doi.org/10.1097/INF.0b013e318199f901.
26. Lee HJ, Huang LM, Togashi T, Juergens C, Amdekar YK, Kieninger DM, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine: population differences observed in Asian, European, and American paediatric studies. Abstract presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Brazil, March 11-15, 2012.
27. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001 8:266-72; PMID:11238206 (Pubitemid 32217054)
28. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356-60; PMID:16522777; http://dx.doi.org/10.1128/CVI. 13.3.356-360.2006.
29. Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940; http://dx.doi.org/10.1128/CVI. 00289-09.
30. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997 4:415-22; PMID:9220157. (Pubitemid 27321773)